Last Updated : April 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Imbruvica | Ibrutinib | |||||
| Xofluza | baloxavir marboxil | Influenza | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | |||
| Imbruvica | ibrutinib | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | ||||
| Admelog | Insulin lispro | Cancelled | ||||
| Xeljanz | tofacitinib | Cancelled | ||||
| Erbitux | Cetuximab | Cancelled | ||||
| TBC | filgrastim | Prevention or treatment of neutropenia in various indications | Cancelled | |||
| TBC | filgrastim | Cancelled | ||||
| TBD | Bevacizumab | Cancelled | ||||
| TBD | Rituximab | Cancelled |
Last Updated : April 19, 2024